Navigation Links
'Smart drug' targets deadly brain cancer

A study led by Mayo Clinic researchers and conducted by the North Central Cancer Treatment Group (NCCTG) reports that a new "smart" drug treatment for an incurable form of recurrent brain cancer slowed tumor growth in more than one-third of the 65 adult patients who tried it. The same research team also developed a screening technique to help predict which patients will respond best to this treatment.

Mayo researchers will present these findings at the 2005 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla. The NCCTG study addressed the most common kind of tumor arising from brain tissue of adults, glioblastoma mutiforme. Current treatment outcomes for this type of cancer are extremely poor: median patient survival is 12 to 16 months, and recurrent disease has a dismal prognosis. The World Health Organization categorizes fast-growing glioblastoma multiforme as a grade IV cancer.

Significance of the Mayo Clinic/NCCTG Research

This discouraging prognosis may change as a result of the rational foundation for new therapies the NCCTG research provides. Study data showed that in 36 percent of patients suffering from recurrent glioblastoma multiforme, the new "smart" drug behaved as hypothesized: It found its target -- tumor cells -- and actively worked against them to slow tumor growth.

According to the study's lead investigator, Mayo Clinic medical oncologist Evanthia Galanis, M.D., "Treatment was well tolerated, and imaging responses were observed in a significant portion (36 percent) of patients with recurrent glioblastoma multiforme participating in this study -- which is a high response rate for this very resistant disease. These early results suggest that we are on to a promising new treatment strategy that could potentially help us improve treatment for patients with recurrent glioblastoma."

Achieving the 36 percent regression rate was an encouraging result -- but researchers didn't stop there. They t
'"/>

Source:Mayor Clinic


Page: 1 2 3

Related biology news :

1. Smart nanoprobes light up disease
2. Smart genetic therapy helps the body to heal itself
3. Anti-inflammatory drugs potentially deadly side effect found to be rare
4. Chemical maps hint at drugs effects on schizophrenia
5. A bacterial genome reveals new targets to combat infectious disease
6. Study reveals candidate targets for anti-retroviral therapeutics
7. NHGRI targets 12 more organisms for genome sequencing
8. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
9. Novel targets found for the development of drugs to complement, or replace, statins
10. Vaccine targets tumors where they live
11. Study findings offer potential new targets for antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Smart drug targets deadly brain cancer

(Date:6/19/2013)... Tanzania is playing a vital role in the survival ... response to climate and environmental changes, according to new ... on savannah birds from the Tanzanian Bird Atlas project ... decades - the researchers found that they are using ... areas further west where dry seasons are getting longer, ...
(Date:6/19/2013)... Science Consortium (PISC) is extremely disappointed that the ... upheld a decision that requires Dow Benelux B.V.to ... The study will use approximately 1160 animals and ... the substance dipropylene glycol methyl ether acetate (DPMA) ... Regulation on the Registration, Evaluation, Authorisation and Restriction ...
(Date:6/19/2013)... A team of researchers at the University of ... outer coating of HIV, that could be potential ... avoid generating resistance. These new agents are quite ... The research was published in the June 2013 ... Chemotherapy . , The first of many probable ...
Breaking Biology News(10 mins):Protected areas provide African birds with stepping stones to survival 2HIV-derived antibacterial shows promise against drug-resistant bacteria 2
... , ANN ARBOR, Mich.---Air pollution from industrial sources ... academic success, according to a new study from ... that schools located in areas with the state,s ... attendance rates---an indicator of poor health---as well as ...
... New findings from University of Utah School of Medicine researchers show ... of patients who have chronic fatigue syndrome (CFS). These findings ... CFS to XMRV. The study, performed by a team of ... associate professor of pathology, was published May 4, 2011, in the ...
... FASEB MARC (Minority Access to Research Careers) Program ... Genetics Society of America (GSA) Mouse Genetics conference in ... are meant to promote the entry of underrepresented minority ... basic science community and to encourage the participation of ...
Cached Biology News:Air pollution near Michigan schools linked to poorer student health, academic performance 2Air pollution near Michigan schools linked to poorer student health, academic performance 3Air pollution near Michigan schools linked to poorer student health, academic performance 4Comprehensive study finds no link between XMRV retrovirus and chronic fatigue syndrome 2Comprehensive study finds no link between XMRV retrovirus and chronic fatigue syndrome 3
(Date:6/19/2013)... Biotechnology industry pioneer Amgen (NASDAQ: ... BlackLine Systems  and enterprise application software leader ... webinar next week entitled "No Account Left Behind!  ... to Help Keep Its Account Reconciliations in Good Shape ... The webinar, geared at finance, accounting, audit and compliance ...
(Date:6/19/2013)... 2013 India’s vast and growing ... be worth up to a billion dollars per ... government is taking serious action to better regulate ... This presentation will examine:, ,     Recent ...     Immediate and long term impacts ,     Foreseeable ...
(Date:6/19/2013)... 19, 2013 Express Diagnostics Int’l, Inc., ... announced that it has received Class III medical device ... its DrugCheck® NxStep Onsite Drug Screen Cup ... rapid screening device in near-patient settings, such as physicians’ ... received Health Canada Class III approval for 24 different ...
(Date:6/18/2013)... A million electric cars could be on roads across North ... of research by the United States Department of Energy, Los ... Zhongwei Chen is part of a team led by the ... replace the expensive platinum catalysts in fuel cells. , "One ... in vehicles is the cost of the units. The pure ...
Breaking Biology Technology:Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3US and Canadian researchers drive towards cheaper fuel cells for electric cars 2
... conductivities seen in metal wires, and that may light up ... researchers. A Rice lab made such a cable from ... standard line voltage -- a true test of the novel ... the future. The work appears this week in ...
... Sept. 7, 2011 Cellectis (Alternext: ALCLS), ... that its nuclease production capacity has increased ... Industrialization of the nuclease manufacturing gives Cellectis ... subsidiary of Cellectis, the potential to supply ...
... 2011 Ardea Biosciences, Inc. (Nasdaq: RDEA ) ... with the U.S. Food and Drug Administration (FDA) and successfully ... lesinurad Phase 3 development plan: the overall size and design ... the total safety database proposed for NDA filing, manufacturing plans ...
Cached Biology Technology:Rice researchers power line-voltage light bulb with nanotube wire 2Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 2Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 2Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 3Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 4Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 5
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
... Physical Form: buffered aqueous solution. ... terminal galactose from complex carbohydrates and glycoproteins. ... galactose under conditions where the pH must ... live cells. Unit Definition: ...
... is specific for human cardiac troponin subunit T, ... signals responsible for contraction of cardiac muscle. It ... in human cells. It also cross-reacts with human ... Antigen: Highly purified human cardiac troponin ...
Biology Products: